These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 21278224)

  • 1. Total recall of radiotherapy with mTOR inhibitors: a novel and potentially frequent side-effect?
    Bourgier C; Massard C; Moldovan C; Soria JC; Deutsch E
    Ann Oncol; 2011 Feb; 22(2):485-6. PubMed ID: 21278224
    [No Abstract]   [Full Text] [Related]  

  • 2. Attributable Risk of Infection to mTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer.
    Garcia CA; Wu S
    Cancer Invest; 2016 Nov; 34(10):521-530. PubMed ID: 27791402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of side effects of mTOR inhibitors in tuberous sclerosis patients.
    Sadowski K; Kotulska K; Jóźwiak S
    Pharmacol Rep; 2016 Jun; 68(3):536-42. PubMed ID: 26891243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lung injury associated with mTOR inhibitors (sirolimus and everolimus).
    Conti V; Grazia M; Romagnoli M; Poletti G; Cristino S; Ciliberti G; Piciucchi S; Mosconi G; Poletti V
    Minerva Urol Nefrol; 2014 Dec; 66(4):283-5. PubMed ID: 25531195
    [No Abstract]   [Full Text] [Related]  

  • 5. Paronychia and pyogenic granuloma induced by new anticancer mTOR inhibitors.
    Sibaud V; Dalenc F; Mourey L; Chevreau C
    Acta Derm Venereol; 2011 Sep; 91(5):584-5. PubMed ID: 21667012
    [No Abstract]   [Full Text] [Related]  

  • 6. mTOR Inhibition and Cardiovascular Diseases: Dyslipidemia and Atherosclerosis.
    Kurdi A; Martinet W; De Meyer GRY
    Transplantation; 2018 Feb; 102(2S Suppl 1):S44-S46. PubMed ID: 28230638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Common toxicities of mammalian target of rapamycin inhibitors.
    Soefje SA; Karnad A; Brenner AJ
    Target Oncol; 2011 Jun; 6(2):125-9. PubMed ID: 21499766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
    Xu J; Tian D
    Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
    Sánchez-Fructuoso AI; Ruiz JC; Pérez-Flores I; Gómez Alamillo C; Calvo Romero N; Arias M
    Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and risk of rash to mTOR inhibitors in cancer patients--a meta-analysis of randomized controlled trials.
    Shameem R; Lacouture M; Wu S
    Acta Oncol; 2015 Jan; 54(1):124-32. PubMed ID: 24914484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mTOR and Cardiovascular Diseases: Diabetes Mellitus.
    Vergès B
    Transplantation; 2018 Feb; 102(2S Suppl 1):S47-S49. PubMed ID: 28263222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues.
    Ferté C; Paci A; Zizi M; Gonzales DB; Goubar A; Gomez-Roca C; Massard C; Sahmoud T; André F; Soria JC
    Eur J Cancer; 2011 Oct; 47(15):2249-55. PubMed ID: 21489779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.
    Somers MJ; Paul E
    J Clin Pharmacol; 2015 Apr; 55(4):368-76. PubMed ID: 25402866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation: does mTOR inhibitors association augment toxicity?
    Perricone G; Mancuso A; Belli LS; Mazzarelli C; Zavaglia C
    Eur J Gastroenterol Hepatol; 2014 May; 26(5):577-8. PubMed ID: 24694739
    [No Abstract]   [Full Text] [Related]  

  • 15. Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma.
    Jebali M; Elaidi R; Brizard M; Fouque J; Takouchop C; Sabatier B; Oudard S; Medioni J
    BMC Cancer; 2017 Jan; 17(1):27. PubMed ID: 28061764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors.
    Choueiri TK; Je Y; Sonpavde G; Richards CJ; Galsky MD; Nguyen PL; Schutz F; Heng DY; Kaymakcalan MD
    Ann Oncol; 2013 Aug; 24(8):2092-7. PubMed ID: 23658373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer.
    Kordes S; Klümpen HJ; Weterman MJ; Schellens JH; Richel DJ; Wilmink JW
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1135-41. PubMed ID: 25822310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus 10 mg and pancreatic neuroendocrine tumours: many adverse effects and uncertain benefit.
    Prescrire Int; 2012 Oct; 21(131):234. PubMed ID: 23185844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. About-face on the metabolic side effects of rapamycin.
    Salmon AB
    Oncotarget; 2015 Feb; 6(5):2585-6. PubMed ID: 25691064
    [No Abstract]   [Full Text] [Related]  

  • 20. Everolimus in renal cell carcinoma.
    Wang Y
    Drugs Today (Barc); 2010 Aug; 46(8):557-66. PubMed ID: 20830316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.